Clinical Trials Logo

Glaucoma, Open-Angle clinical trials

View clinical trials related to Glaucoma, Open-Angle.

Filter by:

NCT ID: NCT00287521 Completed - Ocular Hypertension Clinical Trials

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00284440 Withdrawn - Clinical trials for Primary Open Angle Glaucoma

Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma

Start date: March 2006
Phase: N/A
Study type: Observational

The present study is designed to compare the response of choroidal blood flow to the hand-grip test in glaucoma patients with and without visual field progression.

NCT ID: NCT00283764 Withdrawn - Ocular Hypertension Clinical Trials

Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Start date: n/a
Phase: Phase 3
Study type: Interventional

Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

NCT ID: NCT00280345 Completed - Cataract Clinical Trials

Autoimmune Dysregulation in Pigmentary Glaucoma

Start date: February 2006
Phase: N/A
Study type: Interventional

Based on these recent observations and findings in this new animal model of pigmentary glaucoma in the DBA/2J mouse, we propose that immune system abnormalities in the anterior chamber may play a possible role in the development of pigmentary glaucoma and possibly primary open-angle glaucoma (POAG) in humans.

NCT ID: NCT00277498 Completed - Ocular Hypertension Clinical Trials

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Start date: December 2005
Phase: Phase 3
Study type: Interventional

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

NCT ID: NCT00273481 Completed - Ocular Hypertension Clinical Trials

Cosopt Versus Xalacom

Start date: September 2005
Phase: Phase 4
Study type: Interventional

To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.

NCT ID: NCT00273455 Completed - Open-Angle Glaucoma Clinical Trials

Lumigan Versus Cosopt

Start date: January 2006
Phase: Phase 4
Study type: Interventional

To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

NCT ID: NCT00273442 Completed - Ocular Hypertension Clinical Trials

Assessing Cosopt Switch Patients

Start date: November 2005
Phase: Phase 4
Study type: Interventional

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

NCT ID: NCT00273429 Completed - Ocular Hypertension Clinical Trials

Cosopt Versus Xalatan

Start date: April 2005
Phase: Phase 4
Study type: Interventional

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

NCT ID: NCT00230763 Completed - Ocular Hypertension Clinical Trials

Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

PREDICOM
Start date: September 2005
Phase: Phase 3
Study type: Interventional

To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).